HBV News and Research

RSS

New hepatitis drug much more effective

Chronic infection with the hepatitis B virus (HBV) is responsible for an enormous burden of disease throughout the world, including up to half of all cases of cirrhosis, end-stage liver disease, and hepatocellular carcinoma, a cancer of the liver.

9 Mar 2006

Infants and adolescents vaccinated against hepatitis B are protected for over 10 years after immunisation

...concludes a study in this week’s issue of The Lancet. The authors state that booster doses of vaccine do not seem necessary to ensure long-term protection.

13 Oct 2005

Stressgen granted new U.S. patent for treatment of Hepatitis B

Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted Patent Number 6,921,534 covering fusion protein compositions comprised of a hepatitis B virus (HBV) antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins, and methods of treating an HBV infection using these fusion proteins.

7 Sep 2005

Molecular link between a viral infection and development of a common and fatal form of liver cancer

Researchers at The University of Texas M. D. Anderson Cancer Center have uncovered a crucial molecular link between a viral infection and development of a common and fatal form of liver cancer. In the process, they have identified a possible way to treat this disease as well as a number of other cancers.

26 Jul 2005

Crucial molecular link between a hepatitis B virus (HBV) and hepatocellular carcinoma (HCC)

21 Jul 2005

Sirna Therapeutics granted new UK patents

Sirna Therapeutics has announced that the United Kingdom (UK) Patent Office has granted the Company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with one or more chemical modifications targeting Vascular Endothelial Growth Factor (VEGF).

12 Jul 2005

Study shows using expanded critera donors is safe

Patients who had received livers from hepatitis B virus core antibody (HBcAb) positive (indicates prior exposure to hepatitis B) and/or hepatitis C virus (HCV) positive donors had similar graft and patient survival compared to patients who received HBcAb negative or HCV negative livers, according to a study by the University of Pittsburgh's Thomas E. Starzl Transplantation Institute.

25 May 2005

BMA calls for mass child vaccinations for hepatitis B virus (HBV)

The British Medical Association (BMA) has today called for all children in the UK to be immunised against a potentially fatal liver disease caused by the hepatitis B virus (HBV).

9 May 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B Virus (HBV), an acute sometimes fatal form of viral hepatitis caused by a DNA virus that persists in the blood serum and is transmitted by sexual contact or by transfusion or by ingestion of contaminated blood or other bodily fluids.

14 Feb 2005

Eleventh Edition of the Report on Carcinogens

The Department of Health and Human Services released its Eleventh Edition of the Report on Carcinogens today, adding seventeen substances to the growing list of cancer-causing agents, bringing the total to 246.

31 Jan 2005

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Scientists in Brown Medical School, Providence, USA, have found that core promoter mutants of Hepatitis B Virus e Antigen replicate at up to 10-fold higher levels in transfected human hepatoma cells than the wild-type virus.

9 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

Prevalence of occult HBV in hemodialysis patients is 4 to 5 times higher than standard HBsAg testing would suggest

Some kidney dialysis patients contract hepatitis B virus (HBV) during the course of their treatment, possibly from other members of the dialysis population with occult HBV.

8 Nov 2004

Liver transplantation outcomes have significantly improved for patients with hepatitis B

Since the early 1990s, therapeutic options for patients undergoing liver transplantation for hepatitis B have evolved to include HBV immune globulin (HBIG) and lamivudine.

9 Aug 2004

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HBV) infected patients.

3 Aug 2004

Roche files for application with FDA to market hepatitis C medication Pegasys(R) for chronic hepatitis B treatment

Roche announced today the submission of a supplemental new biologics license application (sBLA) with the U.S. Food and Drug Administration to market Pegasys(R) (peginterferon alfa-2a) for the treatment of chronic hepatitis B (CHB).

21 Jul 2004

Suspension of the initial dose of hepatitis B vaccine appears to have contributed to fewer newborns being vaccinated in 2000

A temporary suspension of the initial dose of hepatitis B vaccine appears to have contributed to fewer newborns being vaccinated for hepatitis B in 2000 than in 1998, according to a study published in the May 19 issue of the Journal of the American Medical Association (JAMA).

22 May 2004

FDA finalizes new rule on donor eligibility for human tissues and cells

FDA today published a final rule establishing donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable disease when these products are transplanted.

20 May 2004

Causes of hepatitis and potential therapies that may improve care presented in study

Hepatitis, a potentially serious disease caused by a virus that attacks the liver, is a major problem worldwide. Hepatitis A is generally food-borne, while hepatitis B and C spread primarily through parenteral or sexual routes. Hepatitis B and C can be life-long, potentially deadly chronic infections.

19 May 2004